Table 2.
Baseline clinical, laboratory, and ART information of children on ART at Bahir Dar city public health facility, Amhara regional state, Northwest Ethiopia (2010–2019).
| Variables | Category | Frequency | Percent |
|---|---|---|---|
| Baseline WHO stage (n = 588) | Stage 1 | 171 | 29.1 |
| Stage 2 | 263 | 44.7 | |
| Stage 3 | 132 | 22.5 | |
| Stage 4 | 22 | 3.7 | |
| Hemoglobin (n = 588) | <8 g/dL | 25 | 4.3 |
| ⩾8 g/dL | 554 | 94.2 | |
| Missing | 9 | 1.5 | |
| W/A (n = 588) | ⩾–2z | 497 | 84.5 |
| <–2z | 91 | 15.5 | |
| H/A (n = 588) | ⩾–2z | 475 | 80.8 |
| <–2z | 111 | 18.9 | |
| Missing | 2 | 0.3 | |
| W/H/L (n = 588) | ⩾–2z | 488 | 83 |
| <–2z | 98 | 16.7 | |
| Missing | 2 | 0.3 | |
| Developmental millstones (n = 588) | Appropriate | 172 | 29.3 |
| Delayed | 17 | 2.9 | |
| Missing | 399 | 67.9 | |
| Functional status (n = 588) | Working | 213 | 36.2 |
| Ambulatory | 178 | 30.3 | |
| Missing | 197 | 33.5 | |
| Opportunistic infection (n = 588) | Yes | 188 | 32 |
| No | 400 | 68 | |
| INH prophylaxis (n = 588) | Yes | 293 | 49.8 |
| No | 290 | 49.3 | |
| Missing | 5 | 0.9 | |
| Cotrimoxazole prophylaxis (n = 588) | Yes | 422 | 71.8 |
| No | 166 | 28.2 | |
| Drug side effect (n = 588) | Yes | 24 | 4.1 |
| No | 564 | 95.9 | |
| Regimen change (n = 588) | Yes | 364 | 61.9 |
| No | 197 | 33.5 | |
| Missing | 27 | 4.6 | |
| Change status (n = 364) | Within the first line | 324 | 55.1 |
| To the second line | 40 | 6.8 | |
| Missing | 224 | 38.1 | |
| CD4 (n = 588) | <200 cells/mm3 | 95 | 16.1 |
| ⩾200 cells/mm3 | 486 | 82.7 | |
| Missing | 7 | 1.2 | |
| Adherence level (n = 588) | Good | 542 | 9.2 |
| Fair | 20 | 3.4 | |
| Poor | 26 | 4.4 | |
| Viral load (n = 588) | <1000 | 472 | 80.3 |
| ⩾1000 | 80 | 13.6 | |
| Missing | 36 | 6.1 |
ART: antiretroviral therapy; WHO: World Health Organization; CD4: cluster of differentiation 4; n: number; INH: isonicotinic acid hydrazide/isoniazide; W/A: weight for age; W/H/L: weight for height/length; H/A: height for age.